A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Stopped early · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Alzheimers Disease
In brief
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Key facts
- Study ID
- NCT02565511
- Run by
- Novartis Pharmaceuticals
- People needed
- 480
- Starts
- 2015-11-30
- Expected to finish
- 2020-04-30
- Last updated by the study team
- 2021-07-08
Who can join
Age: 60 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Phoenix, Arizona, United States
- Novartis Investigative Site — Scottsdale, Arizona, United States
- Banner Sun City Research Institute — Sun City, Arizona, United States
- ATP Clinical Research, Inc. — Costa Mesa, California, United States
- Irvine Center for Clinical Research — Irvine, California, United States
- University of Southern California Keck School of Medicine Alzheimer Disease Research Center — Los Angeles, California, United States
- Novartis Investigative Site — Palo Alto, California, United States
- Novartis Investigative Site — San Diego, California, United States
- Syrentis Clinical Research — Santa Ana, California, United States
- Novartis Investigative Site — Sebastopol, California, United States
- California Neuroscience Research Medical Group, Inc. — Sherman Oaks, California, United States
- Novartis Investigative Site — Temecula, California, United States
- Novartis Investigative Site — Basalt, Colorado, United States
- Yale University Alzheimer's Disease Research Unit — New Haven, Connecticut, United States
- New England Institute for Clinical Research — Stamford, Connecticut, United States
- Georgetown University — Washington D.C., District of Columbia, United States
- Novartis Investigative Site — Washington D.C., District of Columbia, United States
- JEM Research Institute — Atlantis, Florida, United States
- Florida Atlantic University, Clinical Translational Research Unit — Boca Raton, Florida, United States
- Brain Matters Research — Delray Beach, Florida, United States
- Novartis Investigative Site — Jacksonville, Florida, United States
- Meridien Research — Maitland, Florida, United States
- Merritt Island Medical Research — Merritt Island, Florida, United States
- University of Miami — Miami, Florida, United States
- Banner Alzheimer's Institute — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.